News

The Column Group is close to reaching its fundraising target of $600m apiece for its early-stage life science Fund V and later-stage Opportunity Fund III.

I find comfort in knowing that there are people launching new funds to find solutions to problems that affect all of humanity – people like Rosie Wardle, co-founder of Synthesis Capital, a newly launched food technology investor.

Compliance pros shared their real-life nightmare scenarios at PEI’s Private Funds Compliance Forum in New York.

Northern Gritstone, chaired by former Goldman Sachs AM chairman Jim O’Neill, aspires to create jobs and wealth in England’s underfunded North with SDG-aligned seed investments.

In an increasingly competitive market, venture firms can improve their odds of survival by teaming up with larger PE firms with whom they have synergy. This week Sofinnova Partners, a Paris-based early-stage life sciences investor, sold a minority stake to Apollo in return for Apollo committing to invest up to €1 billion to its funds.

As is usually the case, increased rules mean higher compliance costs for those advisers who fall under regulation. For the biggest firms in the industry, those costs can be handled, but for smaller shops, and especially emerging managers, those costs could prove harmful.

Apollo has announced it will buy a minority stake in Paris-based life sciences VC firm Sofinnova Partners, following Carlyle's purchase of Abingworth and EQT's acquisition of LSP.

VC funds performed admirably during the Global Financial Crisis and produced stellar returns in the following years, so you shouldn't be overly concerned about current economic uncertainty.

'About six or seven leading LPs' have joined an effort to create an ESG due diligence questionnaire tailored to the venture capital industry.

Three key climate tech sectors had more than 100 exits in 2021, compared to just a quarter of that number five years ago, signaling that investors are already generating ROI.